Loading company…
Novocardio is a Beijing biotechnology company offering gene sequencing-based genetic testing for cardiovascular diseases.
Established in 2016 and based in Beijing, China, Novocardio provides clinical testing and scientific research collaboration services for cardiovascular diseases. Its work applies to medical treatment, microbiology, animal and plant research and modern agricultural breeding. The company closed a pre-series A funding round in January 2020 and generates revenue from its clinical testing and research collaboration services.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in